From Mesenchymal Stromal Cells to Engineered Extracellular Vesicles: A New Therapeutic Paradigm.
EV therapeutics
MSC-EVs
MSCs
engineered EVs
extracellular vesicles
mesenchymal stromal cells
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
05
2021
accepted:
29
06
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSCs) are multipotent cells obtained from many tissues including bone marrow, adipose tissue, umbilical cord, amniotic fluid, and placenta. MSCs are the leading cell source for stem cell therapy due to their regenerative and immunomodulatory properties, their low risk of tumorigenesis and lack of ethical constraints. However, clinical applications of MSCs remain limited. MSC therapeutic development continues to pose challenges in terms of preparation, purity, consistency, efficiency, reproducibility, processing time and scalability. Additionally, there are issues with their poor engraftment and survival in sites of disease or damage that limit their capacity to directly replace damaged cells. A key recent development in MSC research, however, is the now widely accepted view that MSCs primarily exert therapeutic effects via paracrine factor secretion. One of the major paracrine effectors are extracellular vesicles (EVs). EVs represent a potential cell-free alternative to stem cell therapy but are also rapidly emerging as a novel therapeutic platform in their own right, particularly in the form of engineered EVs (EEVs) tailored to target a broad range of clinical indications. However, the development of EVs and EEVs for therapeutic application still faces a number of hurdles, including the establishment of a consistent, scalable cell source, and the development of robust GMP-compliant upstream and downstream manufacturing processes. In this review we will highlight the clinical challenges of MSC therapeutic development and discuss how EVs and EEVs can overcome the challenges faced in the clinical application of MSCs.
Identifiants
pubmed: 34409037
doi: 10.3389/fcell.2021.705676
pmc: PMC8366519
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
705676Informations de copyright
Copyright © 2021 Johnson, Shojaee, Mitchell Crow and Khanabdali.
Déclaration de conflit d'intérêts
MS, JJ, and RK are employed by Exopharm Ltd. JMC is a contractor to Exopharm Ltd.
Références
Theranostics. 2017 Jan 1;7(1):81-96
pubmed: 28042318
Front Immunol. 2018 Jul 06;9:1583
pubmed: 30034401
PLoS One. 2016 Sep 20;11(9):e0163043
pubmed: 27649079
Mol Ther. 2018 Dec 5;26(12):2838-2847
pubmed: 30341012
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669940
Stem Cell Res Ther. 2018 Jun 19;9(1):170
pubmed: 29921316
Nano Lett. 2021 Feb 24;21(4):1888-1895
pubmed: 33570966
Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81
pubmed: 24321746
Nature. 2007 Jul 19;448(7151):313-7
pubmed: 17554338
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):530-5
pubmed: 25548183
Int J Med Sci. 2018 Jan 1;15(1):36-45
pubmed: 29333086
Transl Stroke Res. 2019 Oct;10(5):509-521
pubmed: 30341718
Front Cell Dev Biol. 2020 Mar 12;8:149
pubmed: 32226787
Bone. 1992;13(1):81-8
pubmed: 1581112
Cell Stem Cell. 2011 Jul 8;9(1):11-5
pubmed: 21726829
Mol Cancer Ther. 2021 Mar;20(3):523-534
pubmed: 33443094
Biomaterials. 2021 Jan;266:120435
pubmed: 33049461
Stem Cells Int. 2012;2012:123030
pubmed: 22645619
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Stem Cells Transl Med. 2015 Sep;4(9):1073-85
pubmed: 26198165
J Extracell Vesicles. 2015 Apr 20;4:26316
pubmed: 25899407
Int Heart J. 2021 Mar 30;62(2):381-389
pubmed: 33731514
Cell Prolif. 2013 Dec;46(6):608-27
pubmed: 24118248
Stem Cell Res. 2010 May;4(3):214-22
pubmed: 20138817
Acta Biomater. 2020 Jun;109:182-194
pubmed: 32305445
Cell Transplant. 2018 May;27(5):765-785
pubmed: 29895169
PLoS One. 2009 Jun 09;4(6):e5846
pubmed: 19513108
Cells. 2018 Dec 16;7(12):
pubmed: 30558352
Adv Healthc Mater. 2021 May 5;:e2100047
pubmed: 33951319
Genes (Basel). 2020 Aug 08;11(8):
pubmed: 32784482
Eur J Pharm Sci. 2017 Jan 1;96:316-322
pubmed: 27720897
Sci Rep. 2018 Aug 17;8(1):12377
pubmed: 30120298
Cell Metab. 2015 Oct 6;22(4):606-18
pubmed: 26365178
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
Leukemia. 2014 Apr;28(4):970-3
pubmed: 24445866
Oncotarget. 2017 Dec 5;8(67):111847-111865
pubmed: 29340096
Front Pharmacol. 2018 Oct 29;9:1199
pubmed: 30420804
Cell Death Dis. 2020 Apr 27;11(4):290
pubmed: 32341353
Mech Ageing Dev. 2008 Mar;129(3):163-73
pubmed: 18241911
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1659-1670
pubmed: 29141446
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
PLoS One. 2013;8(1):e53771
pubmed: 23382851
Sci Rep. 2020 Nov 4;10(1):18996
pubmed: 33149219
PLoS One. 2016 Oct 6;11(10):e0164269
pubmed: 27711256
Stem Cell Res. 2019 Mar;35:101401
pubmed: 30738321
AAPS J. 2017 Nov 27;20(1):1
pubmed: 29181730
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Mol Ther. 2016 Aug;24(7):1290-301
pubmed: 27203438
Oncogene. 2018 Apr;37(16):2137-2149
pubmed: 29367765
Cytotherapy. 2017 Apr;19(4):458-472
pubmed: 28188071
J Extracell Vesicles. 2014 Dec 22;3:25465
pubmed: 25536933
Front Immunol. 2016 Nov 14;7:500
pubmed: 27895644
Stem Cells. 2012 Jul;30(7):1556-64
pubmed: 22605481
FASEB J. 2006 Apr;20(6):661-9
pubmed: 16581974
Sci Rep. 2016 Aug 09;6:31175
pubmed: 27503761
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Int J Mol Sci. 2017 Jun 03;18(6):
pubmed: 28587212
Cell Stem Cell. 2015 Jul 2;17(1):11-22
pubmed: 26140604
Mol Ther. 2011 Jan;19(1):196-203
pubmed: 20842104
Stem Cells. 2019 May;37(5):572-581
pubmed: 30561809
Sci Adv. 2020 Jul 22;6(30):eaba6884
pubmed: 32832666
J Cell Mol Med. 2004 Jul-Sep;8(3):301-16
pubmed: 15491506
Front Pharmacol. 2021 Jan 25;11:590470
pubmed: 33716723
J Extracell Vesicles. 2018 Mar 01;7(1):1440131
pubmed: 29535849
Cell Tissue Kinet. 1970 Oct;3(4):393-403
pubmed: 5523063
Stem Cell Res. 2007 Nov;1(2):129-37
pubmed: 19383393
Cytotherapy. 2021 May;23(5):373-380
pubmed: 33934807
Cells. 2020 Sep 29;9(10):
pubmed: 33003285
Cells. 2020 Mar 09;9(3):
pubmed: 32182815
Stem Cells Transl Med. 2020 Sep;9(9):1068-1084
pubmed: 32496649
Eur Cell Mater. 2014 Sep 22;28:137-51; discussion 151
pubmed: 25241964
Nat Med. 2020 Nov;26(11):1720-1725
pubmed: 32929265
Cytotherapy. 2019 Jun;21(6):581-592
pubmed: 30979664
Int J Nanomedicine. 2017 Apr 18;12:3153-3170
pubmed: 28458537
Cell Biol Toxicol. 2020 Apr;36(2):165-178
pubmed: 31820164
APL Bioeng. 2019 Mar 27;3(1):011503
pubmed: 31069333
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317276
Aging Cell. 2008 Jun;7(3):335-43
pubmed: 18248663
Sci Rep. 2016 Nov 08;6:36162
pubmed: 27824088
Blood. 2003 Apr 15;101(8):2999-3001
pubmed: 12480709
J Am Soc Nephrol. 2009 May;20(5):1053-67
pubmed: 19389847
J Control Release. 2014 Oct 28;192:262-70
pubmed: 25084218
PLoS One. 2013;8(3):e59020
pubmed: 23527076
BMC Neurosci. 2010 Apr 26;11:52
pubmed: 20420688
Theranostics. 2021 Apr 19;11(13):6507-6521
pubmed: 33995671
Bioengineering (Basel). 2019 Jan 16;6(1):
pubmed: 30654439
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Trends Mol Med. 2018 Mar;24(3):242-256
pubmed: 29449149
Pharmaceuticals (Basel). 2021 Apr 09;14(4):
pubmed: 33918628
ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12341-12350
pubmed: 29564886
Mol Ther. 2021 May 5;29(5):1729-1743
pubmed: 33484965
Stem Cells Transl Med. 2019 Nov;8(11):1135-1148
pubmed: 31313507
Sci Adv. 2021 Jan 22;7(4):
pubmed: 33523942
Biomater Res. 2016 Aug 05;20:21
pubmed: 27499886